Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 9/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8502310 | 0.92 | CDK8 (0.47) | CDK8ABL1GSK3AGSK3BPDGFRB | |
| SCHEMBL8499494 | 0.87 | THRB (0.51) | CDK8LMNATP53HCAR2 | |
| SCHEMBL8499164 | 0.85 | PDGFRB (0.52) | CDK8METGSK3AGSK3BPDGFRB | |
| SCHEMBL8501202 | 0.84 | FFAR1 (0.51) | CDK8METPDGFRBPDGFRAHCAR2 | |
| SCHEMBL8502612 | 0.80 | CDK8 (0.58) | CDK8ABL1PDGFRBPDGFRALMNA | |
| SCHEMBL8499069 | 0.80 | GSK3A (0.48) | CDK8ABL1GSK3AGSK3BPDGFRB | |
| SCHEMBL8502204 | 0.78 | THRB (0.51) | CDK8LMNATP53HCAR2 | |
| Hydrochloric Acid SCHEMBL8501955 | 0.77 | PDGFRB (0.49) | METPDGFRBPDGFRA | |
| SCHEMBL8499905 | 0.76 | PDGFRB (0.52) | CDK8GSK3AGSK3BPDGFRBPDGFRA | |
| SCHEMBL8889522 | 0.75 | PDGFRB (0.47) | METPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |